Drug Profile
COVID-19 mRNA vaccine - Biocad
Latest Information Update: 25 Dec 2021
Price :
$50
*
At a glance
- Originator Biocad
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 26 Mar 2020 COVID-19 mRNA vaccine - BIOCAD is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html
- 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in Russia (parenteral)
- 19 Mar 2020 Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020